drugset / Trial / NCT06033131

PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia

NCT06033131 ↗

Phase 3 Recruiting 294 enrolled Lina Bergman The Swedish Research Council · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Preterm preeclampsia is a severe condition for both the mother and the fetus. Currently, the only treatment available to stop disease progression is termination/delivery of the fetus and placenta. Therefore, preterm preeclampsia carries the highest rates of neonatal morbidity and mortality due to iatrogenic preterm birth. There is evidence suggesting metformin, a drug commonly used to treat diabetes in and outside pregnancy, may be able to counter the pathophysiology of preeclampsia, raising the possibility that it could be used to treat the condition. This multi centre double blind randomised controlled trial aims to investigate if metformin can prolong gestation, lower neonatal length of stay and increase birthweight in a Nordic setting.

Timeline

Start
2024-01-19
Primary completion
2027-12-31
Completion
2029-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 1 g Oral

Indications